Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Dose Escalation Study of MK-4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors

NCT01110603 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT01110603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01110603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Dose Escalation Study of MK-4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors
Lead sponsor
Tesaro, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
July 31, 2010
Completion date
July 31, 2011
Enrollment
12 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer: solid tumors